Browse our 1,000+ Publications​

Latest Publications

Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

Marc Raab, et al.
Nature Medicine
June 2026
Authors and Affiliates
Marc S. Raab 1,22 , Niels Weinhold 1,22, K. Martin Kortüm 2, Jan Krönke 3,4, Roland Fenk5, Katja Weisel 6, Lilli Podola1, Uta Bertsch1, Alexander Brobeil7, Julia Mersi2, Stefanie Huhn1, Ryan Arlinghaus8, Michael Hundemer1, Stephan R. Bohl3, Elias K. Mai 1, Natalie Schub9, Johannes Waldschmidt 2, Florian Bassermann 10,11,12, Carsten Müller-Tidow 1, Christoph Heuck13, Caline Sakabedoyan14, Josephine Khan15, Elena Ershova16, Bas D. Koster 17, Monika Engelhardt18, Mathias Hänel19, Hans Salwender 20, Raphael Teipel21, Hartmut Goldschmidt 1, Hermann Einsele 2 & Leo Rasche 2 on behalf of the GMMG-HD10/DSMM-XX (MajesTEC-5) investigators 1Heidelberg Myeloma Center and GMMG Study Group, Department of Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany. 2Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany. 3Department of Hematology, Oncology, and Tumor Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. 4Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Berlin, Berlin, Germany. 5Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. 6University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 7Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. 8Coordination Centre for Clinical Trials (KKS), University Hospital Heidelberg, Heidelberg, Germany. 9Department of Internal Medicine II, Division of Stem Cell Transplantation and Immunotherapy, Universitätsklinikum Schleswig-Holstein (UKSH) Campus Kiel, Kiel, Germany. 10Department of Medicine III, TUM Klinikum, Technische Universität München, München, Germany. 11Deutsches Konsortium für Translationale Krebsforschung (DKTK), Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany. 12Bayerisches Zentrum für Krebsforschung (BZKF), Munich, Germany. 13Johnson & Johnson, Spring House, PA, USA. 14Johnson & Johnson, Paris, France. 15Johnson & Johnson, High Wycombe, UK. 16Johnson & Johnson, Beerse, Belgium. 17Johnson & Johnson, Leiden, The Netherlands. 18Department of Hematology, Oncology and Stem Cell Transplantation, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 19Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany. 20Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona and Asklepios Klinik St. Georg, Hamburg, Germany. 21Medizinische Klinik und Poliklinik I Universitätsklinikum Carl Gustav Carus an der Technische Universität Dresden, Dresden, Germany.

CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission

Aldoss I, et al
Blood Advances
June 2026
Authors and Affiliates
Ibrahim Aldoss 1, Lior Goldberg 2, Jianying Zhang 1, Andrew S Artz 3, Mary C Clark 4, Min Guan 1, Ruby Espinosa 4, Thiruvaimozhi Abimannan 1, Jiaqi Wu 1, Bryan Garcia 1, Eric R Haas 1, Khyatiben V Pathak 5, Brooke Lovell 5, Patrick Pirrotte 5, Vaibhav Agrawal 1, Neguine Sanani 1, Stephanie Kasten 6, Dileshni Tilakawardane 1, Jamie R Wagner 4, Jinny Paul 1, Haoyue Shan 1, Samer Khaled 7, Lihua E Budde 1, Paul B Koller 4, Anthony S Stein 1, Vinod A Pullarkat 8, Amandeep Salhotra 1, Ahmed Aribi 9, Guido Marcucci 10, Xiuli Wang 11, Stephen J Forman 1 1City of Hope National Medical Center, Duarte, California, United States. 2City of Hope, United States. 3City of Hope National Medicine Center, Duarte, California, United States. 4City of Hope, Duarte, California, United States. 5The Translational Genomics Research Institute, Phoenix, Arizona, United States. 6City of Hope National Medical Center, Duarte, Texas, United States. 7City of Hope, San Gabriel, California, United States. 8City of Hope Medical Center, Duarte, California, United States. 9City of hope, Duarte, California, United States. 10Hematologic Malignancies Translational Science, Gehr Family Center for Leukemia Research, City of Hope Medical Center and Beckman Research Institute, Duarte, California, United States. 11City of Hope, Duartte, California, United States.

Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation

Ginosyan A, et al.
Clinical Lymphoma Myeloma & Leukemia
June 2026
Authors and Affiliates
Anush A Ginosyan 1, Karam Ashouri 1, Tiffany Chen 2, Sophie Grove 1, Elaine Huang 1, Brian Hom 1, Vinay Nittur 1, Blake Adnani 1, Jennifer Hwang 1, Mollee Chu 1, Robert Ireland 1, Brandon Ann 1, Lauren Ford 1, Lucas Humayun 1, Arsine Kolanjian 1, Mihir Baya 1, Danielle Hong 1, Preet Chaudhary 2, Imran Siddiqi 3, Amir Ali 4, Karrune Woan 2, Eric Leon Tam 2, George Yaghmour 5 1Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA. 2Jane Anne Nohl Division of Hematology and Center for the Study of Blood Disease, Division of Hematology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. 3Department of Pathology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. 4Department of Pharmacy, University of Southern California (USC), Norris Comprehensive Cancer Center, Los Angeles, CA. 5Jane Anne Nohl Division of Hematology and Center for the Study of Blood Disease, Division of Hematology, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA. Electronic address: george.yaghmour@med.usc.edu.

Talquetamab–Daratumumab in Relapsed or Refractory Myeloma

Mina R, et al.
N Engl J Med
June 2026
Authors and Affiliates
Roberto Mina, M.D.,1,2 Meral Beksac, M.D.,3 Paula Rodríguez‑ Otero, M.D., Ph.D.,4 Wenming Chen, M.D., Ph.D.,5 María‑Victoria Mateos, M.D., Ph.D.,6 Jian Li, M.D.,7 Philippe Moreau, M.D.,8 Yael C. Cohen, M.D.,9,10 Chang‑Ki Min, M.D., Ph.D.,11 Tomas Jelinek, M.D., Ph.D.,12 Jing Christine Ye, M.D.,13 Hila Magen, M.D.,14,15 Samuel M. Rubinstein, M.D.,16 Weijun Fu, M.D., Ph.D.,17 Vania Hungria, M.D., Ph.D.,18 Guldane Cengiz Seval, M.D.,19 Joao Samuel Farias, M.D.,20 Jakub Radocha, M.D.,21 Senem Maral, M.D.,22 Mehmet Turgut, M.D., Ph.D.,23 Youngil Koh, M.D., Ph.D.,24 Daniel O’Leary, M.D.,25 Jayr Schmidt Filho, M.D.,26 Raymond Thertulien, M.D., Ph.D.,27 Gang An, M.D., Ph.D.,28 Shang‑Yi Huang, M.D., Ph.D.,29 Sebastian Grosicki, M.D.,30 Agata Tyczyńska, M.D., Ph.D.,31 Rahul Banerjee, M.D.,32 Matthew J. Pianko, M.D.,33 Joaquín Martínez‑López, M.D., Ph.D.,34 Pawel Steckiewicz, M.D., Ph.D.,35 Dai Maruyama, M.D., Ph.D.,36 Kentaro Fukushima, M.D., Ph.D.,37 Albert Oriol, M.D., Ph.D.,38 Jordi Lopez Pardo, M.D.,39 Hartmut Goldschmidt, M.D.,40 Charlotte Pawlyn, M.D., Ph.D.,41,42 Aurore Perrot, M.D., Ph.D.,43 Elena Zamagni, M.D., Ph.D.,44 Meletios A. Dimopoulos, M.D.,45,46 Leo Rasche, M.D.,47 Jaszianne Tolbert, M.D.,48 William Terry, M.D.,48 Christelle Courtoux, M.Eng.,48 Xiao Liu, M.D.,49 Sandra Y. Vasey, M.S.,48 Kaitlyn Connors, B.S.,50 Mariacristina Festa, M.S.,51 Christoph Heuck, M.D.,48 Angélique Langlois, M.Sc.,48 Lisa O’Rourke, M.S.,48 Jiangxiu Zhou, Ph.D.,48 Xiang Qin, M.S.,48 Jiashen Lu, Ph.D.,52 Joy Gong, Ph.D.,48 Diego Vieyra, Ph.D.,48 and Peter M. Voorhees, M.D.53 1 Division of Hematology, Department of Molecular Biotechnology and Health Sciences, Azienda Ospedaliero-Universitaria Città della Salute e della, Scienza di Torino, University of Turin, Turin, Italy; 2 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta; 3 Istinye University, Ankara University, Ankara, Turkey; 4 Cancer Center Clínica Universidad de Navarra, Cima, Pamplona, Spain; 5 Beijing Chaoyang Hospital, Capital Medical University, Chaoyang District, Beijing; 6 Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca- Consejo Superior de Investigaciones Científicas), Centro de Investigación Biomédica en Red de Cáncer, Salamanca, Spain; 7 Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing; 8 Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France; 9 Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel; 10 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; 11 Seoul St. Mary’s Hospital, Catholic University of Korea, Seoul, South Korea; 12 Department of Hemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic; 13 M.D. Anderson Cancer Center, University of Texas, Houston; 14 Chaim Sheba Medical Center, Ramat-Gan, Israel; 15 Sackler Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; 16 Division of Hematology and Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill; 17 Department of Hematology, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai; 18 Clinica Médica São Germano, São Paulo; 19 Ankara University Faculty of Medicine, Department of Hematology and Oncology, Ankara University, Ankara, Turkey; 20 Liga Paranaense de Combate ao Câncer, Curitiba, Paraná, Brazil; 21 4th Department of Internal Medicine–Hematology, University Hospital Hradec Kralove, Faculty of Medicine in Hradec Kralove, Charles University, Prague, Czech Republic; 22 Medipol Mega University Hospital, Bağcılar, Istanbul, Turkey; 23 Ondokuz Mayıs University, Samsun, Turkey; 24 Seoul National University Hospital, Seoul National University, Jongno-gu, Seoul, South Korea; 25 University of Minnesota, Minneapolis; 26 A.C.Camargo Cancer Center, São Paulo; 27 Novant Health Cancer Institute, Charlotte, NC; 28 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China; 29 National Taiwan University Hospital, National Taiwan University College of Medicine, Zhongzheng District, Taipei; 30 Department of Cancer Prevention, Medical University of Silesia, Katowice, Poland; 31 Medical University of Gdańsk, Department of Hematology and Transplantology and University Clinical Center Gdańsk, Department of Hematology, Transplantology and Cellular Therapies, Gdańsk, Poland; 32 Fred Hutchinson Cancer Center, Seattle; 33 University of Michigan Health, Ann Arbor; 34 Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Complutense University of Madrid, Centro Nacional de Investigaciones Oncológicas, Madrid Institute of Cancer, Madrid; 35 Holy Cross Cancer Center, Department of Hematology and Bone Marrow Transplantation, Kielce, Poland; 36 Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo; 37 University of Osaka Graduate School of Medicine, Suita, Japan; 38 Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias I Pujol, Badalona, Barcelona; 39 l’Hospital de la Santa Creu i Sant Pau, Barcelona; 40 Internal Medicine V, Hematology, Oncology and Rheumatology, German-Speaking Myeloma Multicenter Group Study Group, Heidelberg University Hospital and National Center for Tumor Diseases, Heidelberg, Germany; 41 Institute of Cancer Research, London; 42 Royal Marsden NHS Foundation Trust, London; 43 Universite de Toulouse, Centre Hospitalier Universitaire de Toulouse, Service Hematologie, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France; 44 University of Bologna, Bologna, Italy; 45 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens; 46 Department of Medicine, Korea University, Seoul, South Korea; 47 University Hospital of Würzburg, Würzburg, Germany; 48 Johnson & Johnson, Spring House, PA; 49 Johnson & Johnson, Beijing; 50 Johnson & Johnson, Raritan, NJ; 51 Johnson & Johnson, Leiden, the Netherlands; 52 Johnson & Johnson, Shanghai; 53 Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC.

Clinical and biological implications of TP53 abnormalities inrelapsed/refractory multiple myeloma: the DEDALO study

Montefusco V, et al.
Clin Lymphoma Myeloma Leuk
June 2026
Authors and Affiliates
Vittorio Montefusco, MD1; Anna Maria Cafro, MD2; Gloria Margiotta-Casaluci, MD3; Roberto Mina, MD4; Francesca Patriarca, MD, PhD5; Mattia D’Agostino, MD4; Anna Benedetta Dalla Palma, MD, PhD6; Rita Rizzi, MD7,8; Martina di Trani, MSc9; Paola Bertazzoni, MD2; Gaetano Vaudo, MD10; Maria Teresa Petrucci, MD11; Laura Paris, MD12; Angelo Belotti, MD13; Katia Mancuso, MD, PhD14,15; Concetta Conticello, MD, PhD16; Carmelo Carlo-Stella, MD9,17**; Mario Boccadoro, MD18 1. Hematology Department, ASST Santi Paolo e Carlo, Milano, Italy 2. ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy 3. Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy 4. Division of Hematology, AOU Citta della Salute e della Scienza di Torino, University of Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy 5. Hematologic Clinic and Transplant Center, University Hospital of Central Friuli, DMED, University of Udine, Udine, Italy 6. Hematology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy 7. Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy 8. Hematology and Stem Cell Transplantation Unit, AOU Consorziale Policlinico, Bari, Italy 9. Department of Biomedical Sciences, Humanitas University, Rozzano, Italy 10. Internal Medicine Unit, University of Perugia, Terni–Perugia, Italy 11. Haematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy 12. Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy 13. Department of Haematology, ASST Spedali Civili di Brescia, Brescia, Italy 14. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Sera gnoli”, Bologna, Italy 15. Dipartimento di Scienze Mediche e Chirurgiche, Universita di Bologna, Bologna, Italy 16. Division of Hematology, AOU Policlinico OVE, University of Catania, Catania, Italy 17. Department of Oncology and Hematology, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milano, Italy 18. European Myeloma

CD19/CD22 bivalent CAR T cells in children, adolescents and young adults with B-ALL: final phase 1 trial results

Silbert S, et al.
Journal for ImmunoTherapy of Cancer
June 2026
Authors and Affiliates
Sara K Silbert 1, Flavia Gava 1, Bonnie Yates 1 2, Alexander W Rankin 1 3, Joseph M Rocco 4, Lipei Shao 5, Alexandra Dreyzin 1 5, Yihua Cai 5, Chelsea Lamplugh 1, Kyu Lee Han 5, Michaela Prochazkova 5, Lauren Little 1, Toni Foley 1, Hari Sankaran 6, Kathryn Martin 5, Pamela Garces 5, Ping Jin 5, Christopher D Chien 1, Naomi Taylor 1, Terry J Fry 2, Constance M Yuan 7, Hao-Wei Wang 7, David F Stroncek 5, Steven L Highfill 5, Haneen Shalabi 1, Nirali N Shah 8 1Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA. 2University of Colorado Denver Children's Hospital Colorado Research Institute, Aurora, Colorado, USA. 3Nationwide Children's Hospital, Columbus, Ohio, USA. 4National Institute of Allergy and Infectious Disease, NIH, Bethesda, MD, USA. 5Center for Cellular Engineering, National Institutes of Health, Bethesda, Maryland, USA. 6Biometric Research Program, National Cancer Institute, Bethesda, Maryland, USA. 7Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA. 8Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA nirali.shah@nih.gov.

Daratumumab in Transplant-Ineligible or -Deferred Newly Diagnosed Multiple Myeloma: Minimal Residual Disease in CEPHEUS

Zweegman S, et al.
Blood Advances
June 2026
Authors and Affiliates
Sonja Zweegman,1 Thierry Facon,2 Vania Hungria,3 Nizar J. Bahlis,4 Christopher P Venner,5,6 6 Marc Braunstein,7 Ludek Pour,8 Josep Marti,9 Supratik Basu,10 Yael C. Cohen,11 7 Morio Matsumoto,12 Kenshi Suzuki,13 Cyrille Hulin,14 Sebastian Grosicki,15 Wojciech Legiec,16 8 Meral Beksac,17 Angelo Maiolino,18,19 Hiroyuki Takamatsu,20 Aurore Perrot,21 Mehmet Turgut,22 9 Weiping Liu,23 Jianping Wang,24 Emilie van Brummelen,25 Maria Krevvata,24 10 Lorena LopezMasi,26 Jodi Carey,24 Fredrik Borgsten,26 Melissa Rowe,27 Robin Carson,24 Saad Z Usmani,28 Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center 1 Amsterdam, Amsterdam, The Netherlands; 2 University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; 3 Clínica Médica São Germano, São Paulo, Brazil; 4 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; 5 Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada; 6 BC Cancer – Vancouver Centre, University of British Columbia, Vancouver, BC, Canada 7 Department of Medicine, Division of Oncology-Hematology, NYU Long Island School of Medicine, Perlmutter Cancer Center, NYU Langone Hospital-Long Island, Mineola, NY; 8 University Hospital Brno, Brno, Czech Republic; 9 Hospital Universitario Mútua Terrassa, Barcelona, Spain; 10 Royal Wolverhampton NHS Trust and University of Wolverhampton, Clinical Research Network West Midlands, National Institute for Health Research, Wolverhampton, UK; 11 Department of Hematology, Tel-Aviv Sourasky Medical Center (Ichilov), and Gray Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 12 Department of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan 13 Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan; 14 Department of Hematology, Hôpital Haut-Lévêque, Pessac, France; 15 Department of Cancer Prevention, Faculty of Public Health, Medical University of Silesia, Katowice, Poland; 16 Department of Hematology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Poland; 17 Liv Hospital Ankara, Istinye University, Ankara, Turkey; 18 Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil 19 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil 20 Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan; 21 Université de Toulouse, Centre Hospitalo-Universitaire, IUCT Oncopole, Service d’Hématologie, Toulouse, France; 22 Ondokuz Mayis University, Faculty of Medicine, Samsun, Turkey; 23 Johnson & Johnson, Shanghai, China; 24 Johnson & Johnson, Spring House, PA, USA; 25 Johnson & Johnson, Leiden, The Netherlands; 26 Johnson & Johnson, Raritan, NJ; 27 Johnson & Johnson, High Wycombe, UK; 28 Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study

Muffly L, et al.
Blood
May 2026
Authors and Affiliates
Lori Muffly 1, Noelle V Frey 2, Gregory W Roloff 3, Jae H Park 4, Bhagirathbhai Dholaria 5, Anjali S Advani 6, Veronika Bachanova 7, Ryan D Cassaday 8, Michael Daunov 9, Kaitlyn C Dykes 10, Vivian Irizarry Gatell 11, Michael R Grunwald 12, Talal Hilal 13, LaQuisa C Hill 14, Omer Jamy 15, Vamsi K Kota 16, Muthu Kumaran 17, Chenyu Lin 18, Aaron C Logan 19, Marlise R Luskin 20, Kristen M O'Dwyer 21, Caspian Oliai 22, Olalekan O Oluwole 5, Joshua P Sasine 23, Marc S Schwartz 24, Melhem M Solh 25, Wendy Stock 26, Stephanie B Tsai 27, Matthew L Ulrickson 28, Sumithira Vasu 29, Eunice S Wang 30, Fevzi Firat Yalniz 31, Stephen A Strickland 32, Jessica T Leonard 33, Bijal D Shah 34, Ibrahim Aldoss 35 1Stanford University, Stanford, California, United States. 2Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States. 3The University of Chicago, Chicago, Illinois, United States. 4Memorial Sloan-Kettering Cancer Center, New York, New York, United States. 5Vanderbilt University Medical Center, Nashville, Tennessee, United States. 6Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States. 7University of Minnesota, Minneapolis, Minnesota, United States. 8University of Washington, Seattle, Washington, United States. 9University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, Ohio, United States. 10University of California, San Diego, La Jolla, California, United States. 11UT Southwestern, Dallas, Texas, United States. 12Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States. 13Mayo Clinic, Phoenix, Arizona, United States. 14Baylor College of Medicine, Houston, Texas, United States. 15University of Alabama at Birmingham, Birmingham, Alabama, United States. 16Georgia Cancer Center at Augusta University, Augusta, Georgia, United States. 17University of Arkansas Medical Center, Little Rock, Arkansas, United States. 18Duke University School of Medicine, Durham, North Carolina, United States. 19University of California San Francisco, San Francisco, California, United States. 20Dana-Farber Cancer Institute, Boston, Massachusetts, United States. 21University of Rochester School of Medicine and Dentistry, Rochester, New York, United States. 22Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States. 23Cedars-Sinai Medical Center, Los Angeles, California, United States. 24University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States. 25The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States. 26University of Chicago, Chicago, Illinois, United States. 27Loyola University Medical Center, Maywood, Illinois, United States. 28Banner MD Anderson Cancer Center, Gilbert, Arizona, United States. 29The Ohio State University, Columbus, Ohio, United States. 30Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States. 31University of Kentucky, Lexington, Kentucky, United States. 32SCRI at TriStar Centennial, Nashville, Tennessee, United States. 33Oregon Health Sciences, Portland, Oregon, United States. 34Moffitt Cancer Center, Tampa, Florida, United States. 35City of Hope National Medical Center, Duarte, California, United States.

Brexucabtagene autoleucel consolidation in adult B-cell acute lymphoblastic leukemia: real-world efficacy and toxicity

Jain N, et al.
Blood
May 2026
Authors and Affiliates
Nitin Jain 1, Niranjan Khaire 1, Nicholas Short 1, Shilpa Paul 1, Alexandra Lovell 1, Jayastu Senapati 1, Hannah Goulart 1, Gautam Borthakur 1, Tapan Kadia 1, Koichi Takahashi 1, Naveen Pemmaraju 1, Naval Daver 1, Ghayas Issa 1, Musa Yilmaz 1, Fadi G. Haddad 1, Wei-Ying Jen 1, Rabiul Islam 1, Rebecca Garris 1, Sa Wang 2, Beenu Thakral 2, Partow Kebriaei 3, Bouthaina Dabaja 4, Elizabeth Shpall 3, Sattva Neelapu 5, William Wierda 1, Guillermo Garcia-Manero 1, Farhad Ravandi 1, Hagop Kantarjian 1, Elias Jabbour1 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 2Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 3Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 4Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 5Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Previous Next